Chronic elevations in blood glucose levels in patients with type 2 diabetes may lead to long-term organ damage, including microvascular diseases such as retinopathy, neuropathy, and nephropathy, and may accelerate macrovascular disease, affecting the coronary artery and cerebrovascular and peripheral vascular circulation (1). Improvement in glycemic control can significantly reduce the risks of development and progression of microvascular and, to a lesser extent, macrovascular complications (2,3). However, results from the National Health and Nutrition Examination Survey from 1999 to 2010 and from 2007 to 2010 indicated that almost half of all adults with type 2 diabetes were not at the generally recommended A1C goal of <7.0% (4,5).

The difficulty in achieving glycemic goals may be due, in part, to therapeutic approaches that do not target the underlying pathophysiology. In type 2 diabetes, glucose regulation is disrupted through several different mechanisms, including progressive loss of β-cell function, insulin resistance, inappropriate glucagon secretion, accelerated lipolysis, incretin deficiency and/or resistance, and enhanced glucose reabsorption by the kidneys (6–8). As these disturbances accumulate and worsen, a state of chronic hyperglycemia develops. In recent years, insight into the multiple mechanisms contributing to hyperglycemia in type 2 diabetes has led to the development of new medications targeting one or more of the pathways that are disrupted in type 2 diabetes. Incretin-based therapies, including dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists (7,9), and the newest class of antihyperglycemic agents, the sodium–glucose cotransporter 2 (SGLT2) inhibitors, are prime exam-
examples of targeted therapies for type 2 diabetes (8).

In clinical studies of patients with type 2 diabetes, treatment with the SGLT2 inhibitor canagliflozin has been shown to provide clinically meaningful reductions in A1C, body weight, and blood pressure. These effects were consistently observed in a broad range of patients on different background antihyperglycemic agents, including DPP-4 inhibitors and GLP-1 receptor agonists (10,11). This article provides an overview of the available clinical and real-world data on canagliflozin treatment in patients with type 2 diabetes, both in combination with and compared to incretin-based therapies.

Mechanism of SGLT2 Inhibition

In healthy individuals, the kidneys filter and subsequently reabsorb ~160–180 g of glucose per day. Most renal glucose reabsorption is mediated by SGLT2, which couples sodium and glucose active transport in the early proximal tubule (Figure 1A) (8,12).

In patients who develop chronic hyperglycemia, the renal threshold for glucose excretion (RTG) increases from the normal threshold of ~10.0–11.1 mmol/L (~180–200 mg/dL) in healthy adults to ~13.3 mmol/L (240 mg/dL) in patients with type 2 diabetes, thereby increasing the rate of tubular glucose reabsorption. As a result of these changes, excess glucose is reabsorbed rather than excreted in urine, perpetuating and exacerbating hyperglycemia (8,12).

SGLT2 inhibitors lower the RTG, decreasing the kidneys’ capacity to reabsorb glucose, increasing urinary glucose excretion, and consequently decreasing plasma glucose levels. The ensuing glucosuria also results in a net loss of calories, which can promote weight loss (13). As shown in Figure 1B, in addition to their renal effects, SGLT2 inhibitors have been shown to improve insulin resistance and β-cell function by reducing glucotoxicity (14–16). Canagliflozin also decreases postprandial glucose excursions through a nonrenal mechanism. Immediately after morning dosing, the intestinal concentration of canagliflozin may be high enough to transiently inhibit SGLT1, which may slow glucose absorption from the morning meal and delay the appearance of glucose in plasma (16). Recent studies have also shown that SGLT2 inhibitors increase postprandial plasma glucagon levels, perhaps through inhibition of the SGLT2 transporter on pancreatic α-cells. By decreasing plasma insulin levels and stimulating glucagon secretion, SGLT2 inhibitors may increase endogenous glucose production (14,17). This result suggests that SGLT2 inhibition triggers a physiological response to avoid hypoglycemia, increasing endogenous glucose production such that patients with type 2 diabetes can achieve normal blood glucose levels with minimal risk of hypo-
glycemia (14,17). Because SGLT2 inhibitors act independently from insulin, their mechanism of action is complementary to a range of other antihyperglycemic agents.

**Mechanism of Incretin-Based Therapies**

Incretins (e.g., GLP-1 and gastric inhibitory polypeptide [GIP]) are gut hormones that are secreted in response to food intake and stimulate pancreatic insulin secretion in a glucose-dependent manner (18,19). In addition, GLP-1 has been associated with glucose-dependent inhibition of glucagon secretion, decreased endogenous glucose production, delayed gastric emptying, and increased satiety (18,19).

In healthy individuals, GLP-1 and GIP account for up to 60% of postprandial insulin secretion; however, this effect is markedly reduced in patients with poorly controlled type 2 diabetes (20). In studies of patients with type 2 diabetes, administration of exogenous GLP-1 improved insulin secretion and decreased glucagon secretion in a glucose-dependent manner (21,22). Exogenous GLP-1 was also shown to decrease both fasting and postprandial glucose levels. However, GLP-1 has a short half-life because it is rapidly degraded by DPP-4, making it unsuitable as a pharmacological therapy (20). This result led to the development of GLP-1 receptor agonists, which are resistant to degradation by DPP-4, for the treatment of type 2 diabetes. In parallel, DPP-4 inhibitors were also developed; these agents increase levels and prolong the half-life of active GLP-1 and GIP in circulation (9,19,23).

Incretin-based therapies, including GLP-1 receptor agonists and DPP-4 inhibitors, are generally considered to be weight neutral because they do not promote satiety or decrease appetite (9).

**Clinical Studies of Canagliflozin Versus Sitagliptin**

Two active-controlled, phase 3 studies evaluated canagliflozin compared to the DPP-4 inhibitor sitagliptin in dual therapy with metformin and in triple therapy with metformin plus a sulfonylurea. The study designs and patient populations for these studies, as well as for studies that evaluated clinical outcomes with canagliflozin in combination with incretin-based therapies, are summarized in Table 1. Table 2 provides a summary of the overall safety and adverse events (AEs) reported with canagliflozin in combination with and compared to incretin-based therapies. To date, there have been no head-to-head studies of canagliflozin compared to GLP-1 receptor agonists or to DPP-4 inhibitors other than sitagliptin.

In a randomized, double-blind, four-arm, parallel-group study (ClinicalTrials.gov identifier, NCT01106677), patients with type 2 diabetes inadequately controlled on metformin (n = 1,284) received canagliflozin 100 or 300 mg, sitagliptin 100 mg, or placebo during a 26-week core treatment period; patients in the placebo group were then switched to sitagliptin 100 mg, while those initially on canagliflozin or sitagliptin remained on randomized treatment for an additional 26 weeks (27). At week 52, canagliflozin 100 mg demonstrated noninferiority, and canagliflozin 300 mg demonstrated superiority to sitagliptin 100 mg in A1C lowering (−0.73, −0.88, and −0.73%, respectively). Significant reductions in body weight (−3.3, −3.7, and −1.2 kg, respectively) and systolic blood pressure (−3.5, −4.7, and −0.7 mmHg, respectively) were also seen with canagliflozin 100 and 300 mg versus sitagliptin 100 mg. Consistent with the known safety profile of SGLT2 inhibitors, rates of genital mycotic infections and osmotic diuresis–related AEs were higher with canagliflozin 100 and 300 mg than with sitagliptin 100 mg or placebo/sitagliptin (Table 2).

In a separate randomized, double-blind, active-controlled study (ClinicalTrials.gov identifier, NCT01137812), patients with type 2 diabetes inadequately controlled on metformin plus a sulfonylurea (n = 755) received canagliflozin 300 mg or sitagliptin 100 mg for 52 weeks (28). Canagliflozin 300 mg demonstrated superiority in A1C lowering compared to sitagliptin 100 mg at week 52 (−1.03 vs. −0.66%) and provided significant reductions in body weight (−2.3 vs. 0.1 kg) and systolic blood pressure (−5.1 vs. 0.9 mmHg) (28). Canagliflozin also provided greater reductions in 2-hour postprandial glucose compared to sitagliptin (−3.3 vs. −2.2 mmol/L). Incidences of genital mycotic infections and osmotic diuresis–related AEs were higher with canagliflozin 300 mg than with sitagliptin 100 mg (Table 2). The incidences of documented hypoglycemia were similar with canagliflozin 300 mg and sitagliptin 100 mg, despite an ~0.4% larger reduction in A1C with canagliflozin.

**Clinical Studies of Canagliflozin in Combination With Incretin-Based Therapies**

Two randomized, double-blind, placebo-controlled studies evaluated canagliflozin used in combination with incretin-based therapies for the treatment of type 2 diabetes. The first was a 26-week study (ClinicalTrials.gov identifier, NCT02025907) to assess the efficacy and safety of canagliflozin administered using a dose-titration algorithm in 218 patients with type 2 diabetes inadequately controlled on metformin and sitagliptin (29). The second was a post hoc analysis of the CANAgliflozin cardioVascular Assessment Study (CANVAS; ClinicalTrials.gov identifier, NCT01032629) to evaluate the efficacy and safety of canagliflozin.
over 18 weeks in the subset of patients who were on background therapy that included DPP-4 inhibitors or GLP-1 receptor agonists, with or without other antihyperglycemic agents (11). Key efficacy findings from these 2 studies are presented in Figure 2.

In the 26-week canagliflozin dose-titration study, patients inadequately controlled on metformin and sitagliptin were eligible to increase their dose of canagliflozin from 100 to 300 mg or from placebo to matching placebo starting at week 6 based on prespecified criteria (29). In this study, 90.7% of patients in the canagliflozin group increased their dose from 100 to 300 mg, and 80.2% of patients in the placebo group underwent a mock dose increase. Titrated canagliflozin (pooled 100 and 300 mg) provided superior A1C lowering, weight loss, and systolic blood pressure reduction compared to placebo at 26 weeks as add-on to metformin and sitagliptin (Figure 2). The incidence of female genital mycotic infections and osmotic diuresis–related AEs was numerically higher with canagliflozin than with placebo (Table 2).

In the post hoc analysis of 18-week data from patients enrolled in the CANVAS trial who were on background incretin-based therapy (with or without other antihyperglycemic agents), 316 patients comprised the DPP-4 inhibitor subset and 95 patients comprised the GLP-1 receptor agonist subset (11). In the DPP-4 inhibitor subset, reductions from baseline in A1C, body weight, and systolic blood pressure were seen with canagliflozin 100 and 300 mg compared to placebo. Similar results were observed with canagliflozin 100 and 300 mg compared to placebo in the GLP-1 receptor agonist subset. The incidence of female and male genital mycotic infections and of osmotic diuresis–related AEs was numerically higher with canagliflozin compared to placebo in both the DPP-4 inhibitor and GLP-1 receptor subsets (Table 2).

### TABLE 1. Design and Patient Populations of Studies of Canagliflozin Compared to and in Combination With Incretin-Based Therapies

| Study Description | Key Inclusion Criteria | n | Design |
|-------------------|------------------------|---|--------|
| Add-on to MET versus PBO/SITA (26/52 weeks) (27) | • Age: 18–80 years • A1C ≥ 7.0 to ≤ 10.5% • On stable MET ≥ 2,000 mg/day (or ≥ 1,500 mg/day if unable to tolerate higher dose) | Total = 1,284 | 26-week, double-blind, PBO- and active-controlled, core treatment phase and 26-week, double-blind, active-controlled, extension treatment period after a 2-week, single-blind, PBO run-in period |
| Add-on to MET + SU versus SITA (52 weeks) (28) | • Age: ≥ 18 years • A1C ≥ 7.0 to ≤ 10.5% • On a stable regimen of MET ≥ 2,000 mg/day (or ≥ 1,500 mg/day if unable to tolerate higher dose) + SU (at half-maximal labeled dose or greater) | Total = 756 | 52-week, double-blind, active-controlled treatment period after a 2-week, single-blind, PBO run-in period |
| Add-on to MET + SITA (26 weeks) (29) | • Age: 18–75 years • A1C ≥ 7.5 to ≤ 10.5% • On stable MET ≥ 1,500 mg/day and SITA 100 mg/day | Total = 213 | 26-week, double-blind treatment phase after a 1-week screening period and a 2-week, single-blind, PBO run-in period |
| CANVAS post hoc analysis of patients on DPP-4i/GLP-1RA (18 weeks) (11) | • A1C ≥ 7.0 to ≤ 10.5% (45) • History/high risk of CVD (45) • On stable dose of DPP-4i or GLP-1RA through 18 weeks | Total = 411 | Post hoc analysis of 18-week data in patients taking CANA versus PBO as add-on to incretin-based therapy enrolled in CANVAS (an ongoing, randomized, double-blind, placebo-controlled study of the cardiovascular safety of CANA in 4,330 patients with type 2 diabetes) |

CANA, canagliflozin; CVD, cardiovascular disease; DPP-4i, dipeptidyl peptidase-4 inhibitor; GLP-1RA, glucagon-like peptide-1 receptor agonist; MET, metformin; PBO, placebo; SITA, sitagliptin; SU, sulfonylurea.
TABLE 2. Summary of Overall Safety and Selected AEs With Canagliflozin Compared to and in Combination With Incretin-Based Therapies

|                          | Add-On to MET Versus PBO/SITA (52 weeks) (27) | Add-On to MET + SU Versus SITA (52 weeks) (28) | Add-On to MET Versus PBO (26 weeks) (29) | CANVAS Add-On to Incretin-Based Therapies Versus PBO: DPP-4i Subset (18 weeks) (11) | CANVAS Add-On to Incretin-Based Therapies Versus PBO: GLP-1RA Subset (18 weeks) (11) |
|--------------------------|-----------------------------------------------|-----------------------------------------------|------------------------------------------|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
|                          | PBO/SITA, n = 183                            | SITA 100 mg, n = 366                          | CANA 100 mg, n = 368                      | CANA 300 mg, n = 367                                                                    | CANA 100 mg, n = 102                                                                |
|                          | (66.7)                                       | (64.5)                                        | (72.3)                                   | (62.7)                                                                               | (58.8)                                                                               |
|                          | SITA 293                                     | 289                                           | (77.5)                                   | 48                                                                                   | 43                                                                                   |
|                          | 100 mg, n = 378                              | (76.7)                                        |                                         | (39.8)                                                                               |                                                                                      |
|                          | CANA 48                                      | 43                                            |                                         |                                         |                                         |
|                          | 267                                           |                                               |                                         |                                         |                                         |
|                          | CANA 60                                      | 66                                            | (61.4)                                   | 70                                                                                   | 70                                                                                   |
|                          | 63.1                                          |                                               |                                         | (63.1)                                                                               |                                                                                      |
|                          | CANA 23                                      | 22                                            | (62.9)                                   | 22                                                                                   | 22                                                                                   |
|                          | 73.3                                          |                                               |                                         |                                                                                      |                                                                                      |
| Any AE                   | 122                                           | 236                                           | 266                                      | 230                                                                                  | 293                                                                                  |
|                          | (66.7)                                       | (64.5)                                        | (72.3)                                   | (62.7)                                                                               | (77.5)                                                                               |
|                          | PBO/SITA, n = 368                            | SITA 100 mg, n = 368                          | CANA 100 mg, n = 368                      | CANA 300 mg, n = 367                                                                    | CANA 100 mg, n = 102                                                                |
|                          | (66.7)                                       | (64.5)                                        | (72.3)                                   | (62.7)                                                                               | (58.8)                                                                               |
|                          | SITA 293                                     | 289                                           | (77.5)                                   | 48                                                                                   | 43                                                                                   |
|                          | 100 mg, n = 378                              | (76.7)                                        |                                         | (39.8)                                                                               |                                                                                      |
|                          | CANA 48                                      | 43                                            |                                         |                                         |                                         |
|                          | 267                                           |                                               |                                         |                                         |                                         |
|                          | CANA 60                                      | 66                                            | (61.4)                                   | 70                                                                                   | 70                                                                                   |
|                          | 63.1                                          |                                               |                                         | (63.1)                                                                               |                                                                                      |
|                          | CANA 23                                      | 22                                            | (62.9)                                   | 22                                                                                   | 22                                                                                   |
|                          | 73.3                                          |                                               |                                         |                                                                                      |                                                                                      |
| Any AE                   | 8 (4.4)                                      | 16 (4.4)                                      | 19 (5.2)                                 | 12 (3.3)                                                                             | 11 (1.0)                                                                             |
|                          | (4.4)                                         | (4.4)                                         | (5.2)                                    | (3.3)                                                                                | (1.0)                                                                                |
| AEs leading to            | 8 (4.4)                                      | 16 (4.4)                                      | 19 (5.2)                                 | 12 (3.3)                                                                             | 11 (1.0)                                                                             |
| discontinuation          | (4.4)                                         | (4.4)                                         | (5.2)                                    | (3.3)                                                                                | (1.0)                                                                                |
| AEs related to           | 23 (12.6)                                    | 72 (19.7)                                     | 97 (26.4)                                | 73 (19.9)                                                                            | 105 (52.8)                                                                           |
| study drug*              | (12.6)                                       | (19.7)                                        | (26.4)                                   | (19.9)                                                                               | (52.8)                                                                               |
| Serious AEs              | 7 (3.8)                                      | 18 (4.9)                                      | 15 (4.1)                                 | 12 (3.3)                                                                             | 21 (5.6)                                                                             |
| Deaths                   | 1 (0.5)                                      | 1 (0.3)                                       | 0 (0.0)                                  | 1 (0.3)                                                                              | 0 (0.0)                                                                              |
| Selected AEs             | 12 (6.6)                                     | 23 (6.3)                                      | 29 (7.9)                                 | 18 (4.9)                                                                             | 21 (5.6)                                                                             |
| UTIs                     | (6.6)                                         | (6.3)                                         | (7.9)                                    | (4.9)                                                                                | (5.6)                                                                                |
| Genital mycotic          | 1 (1.1)                                      | 2 (1.2)                                       | 9 (5.2)                                  | 4 (2.4)                                                                              | 1 (0.5)                                                                              |
| infections               | (1.1)                                         | (1.2)                                         | (5.2)                                    | (2.4)                                                                                | (0.5)                                                                                |
| Men†                     | 1 (1.1)                                      | 2 (1.2)                                       | 9 (5.2)                                  | 4 (2.4)                                                                              | 1 (0.5)                                                                              |
|                          | (1.1)                                         | (1.2)                                         | (5.2)                                    | (2.4)                                                                                | (0.5)                                                                                |
| Women‡                   | 1 (1.1)                                      | 5 (2.6)                                       | 22 (11.3)                                | 20 (9.9)                                                                             | 7 (4.3)                                                                              |
|                          | (1.1)                                         | (2.6)                                         | (11.3)                                   | (9.9)                                                                                | (4.3)                                                                                |
| Osmotic diuresis–related | 1 (0.5)                                      | 7 (1.9)                                       | 30 (8.2)                                 | 16 (4.4)                                                                             | 9 (2.4)                                                                              |
| AEs§                     | (0.5)                                         | (1.9)                                         | (8.2)                                    | (4.4)                                                                                | (2.4)                                                                                |
| Volume depletion–related | 1 (0.5)                                      | 7 (1.9)                                       | 4 (1.1)                                  | 3 (0.8)                                                                              | 8 (2.1)                                                                              |
| AEs¶                     | (0.5)                                         | (1.9)                                         | (1.1)                                    | (0.8)                                                                                | (2.1)                                                                                |
| Hypoglycemia episodes    | 5 (2.7)                                      | 15 (4.1)                                      | 25 (6.8)                                 | 25 (6.8)                                                                             | 154 (40.7)                                                                            |
| Documented‡,‡             | (2.7)                                         | (4.1)                                         | (4.1)                                    | (4.1)                                                                                | (40.7)                                                                               |
| Severe‡                  | 0 (0.0)                                      | 1 (0.3)                                       | 1 (0.3)                                  | 0 (0.0)                                                                              | 13 (3.4)                                                                             |
|                          | (0.0)                                         | (0.3)                                         | (0.3)                                    | (0.0)                                                                                | (3.4)                                                                                |
| All data are shown as number of patients (%). *Possibly, probably, or very likely related to study drug, as assessed by investigators. †Includes genital infection female, genital candidiasis, genital infection fungal, penile infection, and posthitis. ‡Includes genital infection male, genital candidiasis, genital infection fungal, vaginal infection, vaginal inflammation, vulvitis, vulvovaginal candidiasis, vulvovaginal mycotic infection, and vulvovaginitis. §Includes dry mouth, micturition disorder and urgency, nocturia, pollakiuria, polydipsia, polyuria, thirst, and urine output increased. ||Includes blood pressure decreased, dehydration, postural dizziness, hypotension, orthostatic hypotension, presyncpe, syncope, and urine output decreased. ¶Including biochemically documented episodes (fingertip or plasma glucose ≤3.9 mmol/L [≤70 mg/dL] with or without symptoms) of hypoglycemia was infrequent in patients who were not on background insulin or insulin secretagogues (≤1 episode in all treatment groups; no episodes were severe). #For the CANVAS study, hypoglycemia episodes are reported for the subset of patients on background insulin or insulin secretagogues; documented hypoglycemia was infrequent in patients who were not on background insulin or insulin secretagogues (≤1 episode in all treatment groups; no episodes were severe). CANA, canagliflozin; DPP-4i, dipeptidyl peptidase-4 inhibitor; GLP-1RA, glucagon-like peptide-1 receptor agonist; MET, metformin; PBO, placebo; SITA, sitagliptin; SU, sulfonylurea; UTI, urinary tract infection.
## Feature Article

### A

| Condition                        | n  | Baseline (%) | LS mean change (±SE) from baseline in A1C (%) |
|----------------------------------|----|--------------|---------------------------------------------|
| Add-on to MET + SITA (26 weeks) | 94 | 8.4          | -0.89% (95% CI: -1.19, -0.59)               |
| CANVAS DPP-4i subset (18 weeks)  | 99 | 8.5          | -0.56% (95% CI: -0.77, -0.35)               |
| CANVAS GLP-1RA subset (18 weeks)| 96 | 8.1          | -0.75% (95% CI: -0.95, -0.54)               |

### B

| Condition                        | n  | Baseline (kg) | LS mean % change (±SE) from baseline in body weight |
|----------------------------------|----|---------------|-----------------------------------------------------|
| Add-on to MET + SITA (26 weeks)  | 104| 89.9          | -1.6% (-1.6 kg)                                      |
| CANVAS DPP-4i subset (18 weeks)  | 103| 93.8          | -3.4% (-3.1 kg)                                      |
| CANVAS GLP-1RA subset (18 weeks)| 100| 88.6          | -2.3% (-2.7 kg)                                      |

### Diagram

- PBO
- Titrated CANA*
- CANA 100 mg
- CANA 300 mg

*(pooled 100/300 mg)*
Interpretation of findings from the CANVAS post hoc analysis was limited by the relatively small numbers of patients on background therapy with DPP-4 inhibitors or GLP-1 receptor agonists and by the relatively short duration of treatment (11). However, findings from this analysis (11) and from the 26-week add-on to metformin/sitagliptin dose-titration study (29) provide evidence of clinically meaningful reductions in A1C, body weight, and systolic blood pressure in patients with type 2 diabetes on regimens that include incretin-based therapies. The benefits of SGLT2 inhibitors in combination with DPP-4 inhibitors are also supported by data from studies of dapagliflozin in combination with metformin and sitagliptin or saxagliptin (30–32) and of a fixed-dose combination of empagliflozin 10 mg with linagliptin 5 mg, which has been shown to be more effective than either agent as monotherapy or as add-on to metformin (33,34).

### Real-World Evidence Comparing Canagliflozin and Incretin-Based Therapies

In a retrospective, matched-control cohort study (n = 5,532) that used integrated claims and laboratory data from a large, geographically diverse U.S. population of patients enrolled in commercial and Medicare Advantage health plans, the effectiveness of canagliflozin (pooled 100 and 300 mg) compared to DPP-4 inhibitors (sitagliptin, saxagliptin, linagliptin, and alogliptin) was evaluated over a 9-month period (35). The analysis included adults with ≥1 pharmacy claim for canagliflozin or a DPP-4 inhibitor as monotherapy or combination therapy and ≥1 medical claim with a diagnosis of type 2 diabetes during the study period; there were no selection criteria related to estimated glomerular filtration rate (eGFR). Patients in each cohort were stratified based on A1C status, and then propensity score matching was used to match patients by incorporating various parameters.

Among matched patients with a baseline A1C ≥7.0% (n = 1,656), mean time to follow-up was 184.2 days and 182.3 days in the canagliflozin and DPP-4 inhibitor cohorts, respectively (35). At follow-up, canagliflozin treatment was associ-
ated with a greater mean reduction in A1C compared to DPP-4 inhibitors (Figure 3). After adjusting for residual differences in baseline characteristics, mean reductions in A1C remained greater for patients treated with canagliflozin 100 and 300 mg than for those treated with DPP-4 inhibitors. In a subgroup analysis of canagliflozin compared to sitagliptin, A1C reductions in matched patients with a baseline A1C ≥7.0% were consistent with the analysis versus all DPP-4 inhibitors (Figure 3).

No direct head-to-head comparisons are available between canagliflozin and GLP-1 receptor agonists. A recent retrospective U.S. claims database analysis examined treatment persistence with canagliflozin compared to incretin-based therapies in patients who had a first claim in 2013 for canagliflozin, sitagliptin, saxagliptin, linagliptin, liagalutide, exenatide, or long-acting exenatide. Findings from this analysis indicate that patients taking canagliflozin tend to stay on treatment longer than those taking DPP-4 inhibitors or GLP-1 receptor agonists. Data from the Truven database of commercially insured patients (n = 66,206) showed that, after 12 months, 64.0% of patients prescribed canagliflozin 100 mg and 65.0% of patients prescribed canagliflozin 300 mg remained on treatment, compared to 30.2% with linagliptin, 51.1% with sitagliptin, 24.3% with exenatide, and 43.0% with liagalutide (P <0.0001 for all comparisons) (36). The likelihood of treatment discontinuation (based on mean adjusted hazard ratios) was shown to be higher for sitagliptin, saxagliptin, linagliptin, exenatide, long-acting exenatide, and liagalutide than for canagliflozin. A limitation of this analysis is that, for much of the timeframe evaluated, canagliflozin was the only SGLT2 inhibitor approved for use in the United States, so patients had only one treatment option in this drug class but had several choices of DPP-4 inhibitors and GLP-1 receptor agonists.

Considerations for Use of Canagliflozin and Incretin-Based Therapies in Clinical Practice

Consistent with current type 2 diabetes practice guidelines, clinicians should implement a patient-centered approach to disease management. When setting individualized glycemic goals and selecting therapies, treatment strategies should be designed to optimize the patient’s overall benefit/risk profile. Key factors to consider when developing individualized treatment plans include age, disease duration, comorbidities, renal function, patient preferences for and attitudes toward treatment, and availability of health care resources and support (18,24,25).

The American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) and American Association of Clinical Endocrinologists (AACE)/American College of Endocrinology (ACE) treatment algorithms recommend SGLT2 inhibitors both as monotherapy, when metformin is contraindicated or not tolerated, and as part of dual and triple combination therapy with metformin (18,24,25). After metformin, AACE/ACE guidelines recommend the following agents as initial monotherapy (in order of preference): GLP-1 receptor agonists, SGLT2 inhibitors, DPP-4 inhibitors, thiazolidinediones, α-glucosidase inhibitors, and sulfonylureas (25).

The effects of SGLT2 inhibitors are independent of insulin secretion, thus making them a suitable option for patients with more advanced type
**TABLE 3. Patient Populations That May Benefit Most From Treatment With an SGLT2 Inhibitor Instead of or in Addition to Incretin-Based Therapies**

| Patients likely to benefit from treatment: |
|------------------------------------------|
| • Patients with normal kidney function  |
| • Patients intolerant to metformin        |
| • Patients requiring add-on therapy to metformin because they are not at goal |
| • Newly diagnosed patients with an A1C >9% requiring initial combination therapy with metformin plus a second antihyperglycemic agent |
| • Patients requiring a third antihyperglycemic agent because they are not at goal with dual therapy |

| Patients for whom canagliflozin should be used with caution: |
|-------------------------------------------------------------|
| • Patients with moderate renal impairment                   |
| • Elderly patients                                           |
| • Patients prone to genital mycotic infections               |
| • Patients taking loop diuretics or with other risk factors for dehydration |

2 diabetes. However, given their renal mechanism of action, patient kidney function should be assessed before and periodically during treatment with these agents. In patients with an eGFR <45 mL/min/1.73 m², clinical data indicate that the efficacy of canagliflozin is reduced (25) and the risk of volume-related AEs is increased. Therefore, use of canagliflozin is not recommended in patients with an eGFR <45 mL/min/1.73 m². In such cases, treatment with adjusted doses of some DPP-4 inhibitors may be a suitable alternative. GLP-1 receptor agonists should be used with caution in patients with renal impairment because there have been postmarketing reports of acute renal failure and worsening of chronic renal failure, usually in patients who experienced nausea, vomiting, diarrhea, or dehydration.

In addition to improving glycemic control, canagliflozin has demonstrated beneficial effects on multiple risk factors commonly observed in patients with type 2 diabetes, including reducing body weight and visceral adiposity, blood pressure, albuminuria, and uric acid levels. Canagliflozin has shown favorable effects on some lipid parameters, including reducing triglycerides and increasing HDL cholesterol; however, canagliflozin is associated with dose-related increases in LDL cholesterol levels (37–43). The mechanism of increased LDL cholesterol is unknown but may be related to modest hemo-concentration due to osmotic diuresis (44). Additional information on the overall and cardiovascular safety of canagliflozin will be obtained from the CANVAS Program, including CANVAS and CANVAS-R (renal endpoints; ClinicalTrials.gov identifier, NCT01989754), upon completion in 2017 (45–47).

Overall, canagliflozin is generally well tolerated, with favorable real-world persistence rates compared to incretin-based therapies (36). The most common side effects observed in patients treated with canagliflozin are related to the mechanism of SGLT2 inhibition (i.e., genital mycotic infections and volume depletion–related AEs); these AEs are usually mild or moderate in intensity, tend to occur early in the course of treatment and decrease over time, and can be managed using standard treatments (13).

There have been postmarketing reports of urosepsis and pyelonephritis in patients receiving SGLT2 inhibitors (48). Across pooled placebo-controlled studies, the incidence of urinary tract infections was modestly higher with canagliflozin 100 and 300 mg compared to placebo; however, there was no increase in serious urinary tract infections with canagliflozin versus placebo (43,49).

The U.S. Food and Drug Administration has also issued safety warnings for SGLT2 inhibitors based on postmarketing reports of acute kidney injury and diabetic ketoacidosis (DKA) with all marketed SGLT2 inhibitors (50–52), and bone fractures with canagliflozin (53). In addition, interim results from CANVAS showed higher rates of amputations (mostly toes) with canagliflozin than with placebo (54). After the postmarketing reports of DKA and bone fractures, post hoc analyses of pooled clinical trial data were conducted to better understand these risks. In an analysis of data from completed and ongoing randomized controlled trials of canagliflozin (n = 17,956 patients with nearly 24,000 patient-years of exposure), the incidence of DKA was 0.07% with canagliflozin 100 mg, 0.11% with canagliflozin 300 mg, and 0.03% with comparators (55). These rates are consistent with observed rates of DKA in general populations of patients with type 2 diabetes (55).

In a separate analysis of >10,000 patients enrolled in nine phase 3 studies, a non–dose-dependent increase in fractures was seen with canagliflozin versus comparators that was driven by results in the CANVAS trial (56). Fractures generally occurred early after treatment initiation, and most fractures were located in distal parts of the upper
and lower extremities and not in typical osteoporotic regions, such as the hips and spine. Although it is unclear whether the increased fracture risk seen with canagliflozin is an SGLT2 inhibitor class effect, an imbalance in upper limb fractures (i.e., humerus, wrist, upper limb, and forearm) was reported with empagliflozin versus placebo in the EMPA-REG OUTCOME (ClinicalTrials.gov identifier, NCT01131676) trial, although the overall rate of fractures was similar between groups (57, 58). An early increased risk of fractures was also seen with dapagliflozin in a 104-week study in 252 patients with type 2 diabetes and moderate renal impairment (51).

Incretin-based therapies are also generally well tolerated. DPP-4 inhibitors have favorable safety profiles, with much lower rates of gastrointestinal side effects compared to GLP-1 receptor agonists and a low propensity to cause hypoglycemia. However, cases of serious hypersensitivity reactions, including Stevens-Johnson syndrome, as well as angioedema, urticaria, bronchial hyperreactivity, and other immune-mediated dermatological effects have been reported rarely with DPP-4 inhibitors (26). Common side effects of GLP-1 receptor agonists are nausea and vomiting, and hypoglycemia has been reported in clinical studies of these agents, especially when used in combination with sulfonylureas or insulin (59). For many patients, the benefits of GLP-1 receptor agonists outweigh the risks, given their favorable effects on body weight, blood pressure, and lipids (59). Pancreatitis may be a concern with incretin-based therapies, although reported events with GLP-1 receptor agonists and DPP-4 inhibitors have been rare. Ongoing studies are being performed to clarify this potential risk (26).

Table 3 provides an overview of the types of patients for whom treatment with an SGLT2 inhibitor in addition to or instead of incretin-based therapies may be most beneficial. Based on the current understanding of the mechanism of action, as well as safety and efficacy data, and considering patient convenience and personal choices, it appears that SGLT2 inhibitors would be a reasonable alternative for any patient with type 2 diabetes who is not at goal (i.e., A1C > 7.0%) when treated with ≥1 oral antihyperglycemic agent. Candidates must have adequate renal function (i.e., eGFR > 60 mL/min/1.73 m²) and no known allergies to the drugs. SGLT2 inhibitors may also be appropriate for use earlier in the course of the disease, as long as patients are aware of the risks of genital mycotic infections, transient polyuria with mild dehydration, and infections of the lower urinary tract. In general, the durability of the glucose-lowering effect with the potential for delaying the deterioration of B-cell function, in addition to reductions in body weight and blood pressure, are appealing attributes that support the selection of SGLT2 inhibitors as early therapy in patients with type 2 diabetes.

**Potential for Cardiometabolic Benefits With Incretins and SGLT2 Inhibitors**

Results from large-scale cardiovascular safety studies of incretin-based therapies and SGLT2 inhibitors in patients at high risk for cardiovascular events are starting to emerge and, coupled with those from several ongoing studies, will provide a more complete picture of the cardiometabolic effects of these classes of antihyperglycemic agents.

Recently published results from the LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results; ClinicalTrials.gov identifier, NCT0179048) study demonstrated that liraglutide significantly reduced the rate of the first occurrence of a composite of death from cardiovascular causes, nonfatal myocardial infarction, and nonfatal stroke compared to placebo in patients with type 2 diabetes (60). These data suggest that some GLP-1 receptor agonists may have the potential to improve long-term cardiovascular outcomes in patients with diabetes and high cardiovascular risk. Studies with DPP-4 inhibitors (i.e., SAVOR-TIMI 53 [Saxagliptin Assessment of Vascular Outcomes Recorded on Patients with Diabetes Mellitus; ClinicalTrials.gov identifier, NCT01107886] [61], EXAMINE [EXamination of Cardiovascular Outcomes with Sitagliptin; ClinicalTrials.gov identifier, NCT00790205] [62], and the TECOS [Trial Evaluating Cardiovascular Outcomes with Sitagliptin; ClinicalTrials.gov identifier, NCT00968708] [63]) have shown that DPP-4 inhibitors do not appear to increase the risk of overall cardiovascular events compared to placebo in patients with type 2 diabetes and established cardiovascular disease. However, saxagliptin was associated with an increased risk of hospitalization for heart failure compared to placebo (61).

Encouraging results on the cardiometabolic benefits of SGLT2 inhibitors have been reported from the EMPA-REG OUTCOME trial. Results of this study showed that empagliflozin was associated with a 14% reduction in the three-point major adverse cardiovascular event primary outcome, which was primarily driven by a 38% reduction in cardiovascular death (57). Additionally, results from a secondary prespecified analysis of renal outcomes showed that patients treated with empagliflozin for a median duration of 2.6 years experienced slower progression of kidney disease compared to placebo (64). Findings from this analysis are consistent with the hypothesis that SGLT2 inhibitors have the potential to provide renoprotection, perhaps through direct effects on renal hypertension and hyperfiltration and on renal tubular inflammation and hypertension, as well as via indirect effects on glycemic control, body weight, and systolic blood pressure reduc-
tions, improved insulin sensitivity, and lowering of serum uric acid levels (65,66). Additional data on possible renoprotective mechanisms of SGLT2 inhibition are expected from the phase 3 CREDEnCE study (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation; ClinicalTrials.gov identifier, NCT02065791), which is evaluating whether canagliflozin 100 mg can slow the progression of diabetic nephropathy in patients with type 2 diabetes and stage 2 or stage 3 chronic kidney disease and macroalbuminuria who are receiving therapy according to standards of care.

Conclusion
SGLT2 inhibitors and incretin-based therapies have emerged as excellent choices to control hyperglycemia in a broad range of patients with type 2 diabetes (18,24,25). In clinical and real-world studies, canagliflozin has demonstrated superior A1C lowering compared to sitagliptin. Unlike sitagliptin and other DPP-4 inhibitors, treatment with canagliflozin can promote modest weight loss and blood pressure reduction. Adding canagliflozin to treatment regimens that include a DPP-4 inhibitor or a GLP-1 receptor agonist has been shown to further improve glycemic control and to have additional beneficial effects on cardiometabolic parameters such as body weight and blood pressure. Overall, the available clinical and real-world evidence on the use of canagliflozin compared to or in addition to incretin-based therapies supports canagliflozin as a safe and well-tolerated treatment option to be considered for use with or instead of incretin-based therapies.

Duality of Interest
E.C. has served on speakers bureaus for the Boehringer Ingelheim/Eli Lilly Alliance, Janssen Pharmaceuticals, AstraZeneca, and Sanofi; has served on advisory boards for the Boehringer Ingelheim/Eli Lilly Alliance and Sanofi; and has received research funding from Janssen Pharmaceuticals and AstraZeneca. No other potential conflicts of interest were reported.

References
1. Fowler MJ. Microvascular and macrovascular complications of diabetes. Clinical Diabetes 2008;26:77–82
2. U.K. Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–853
3. U.K. Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854–865
4. Stark Casagrande S, Fradkin JE, Saydah SH, Rust JK, Cowie CC. The prevalence of A1C, blood pressure, and LDL goals among people with diabetes, 1988–2010. Diabetes Care 2013;36:2271–2279
5. Ali MK, Bullard KM, Saadinne JB, Cowie CC, Imperatore G, Gregg EW. Achievement of goals in U.S. diabetes care, 1999–2010. N Engl J Med 2013;368:1613–1624
6. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am 2004;88:787–835, ix
7. Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 2014;383:1068–1083
8. Wilding JP. The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors. Metabolism 2014;63:1228–1237
9. Freeman JS. A physiologic and pharmacological basis for implementation of incretin hormones in the treatment of type 2 diabetes mellitus. Mayo Clin Proc 2010;85(12 Suppl.3:S5–S14
10. Rosenthal N, Meininger G, Ways K, et al. Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus. Ann N Y Acad Sci 2015;1358:28–43
11. Fulcher G, Matthews DR, Perkovic V, et al. Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes. Diabetes Obes Metab 2016;18:82–91
12. Cersosimo E, Solis-Herrera C, Triplitt C. Inhibition of renal glucose reabsorption as a novel treatment for diabetes patients. J Bras Nefrol 2014;36:80–92
13. Muraliar S, Polidori D, Zambrovicz B, Henry RR. Sodium-glucose co-transporter inhibitors: effects on renal glucose transport: from bench to bedside. Diabetes Care 2015;38:2344–2353
14. Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose co-transporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014;124:499–508
15. Polidori D, Mari A, Ferrannini E. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes. Diabetologia 2014;57:891–901
16. Polidori D, Sha S, Muraliar S, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med 2015;21:512–517
17. Bonner C, Kerr-Conte J, Gmyr V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med 2015;21:512–517
18. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140–149
19. Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 2008;60:470–512
20. Chia CW, Egan JM. Role and development of GLP-1 receptor agonists in the management of diabetes. Diabetes Metab Syndr Obes 2009;2:37–49
21. Brubaker PL, Drucker DJ. Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology 2004;145:2653–2659
22. Egan JM, Bulotta A, Hui H, Perfetti R. GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells. Diabetes Metab Res Rev 2003;19:115–123
23. Harris KB, McCarty DJ. Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus. Ther Adv Endocrinol Metab 2015;6:3–18
24. American Diabetes Association. Standards of Medical Care in Diabetes—2016. Diabetes Care 2016;39(Suppl. 1):S1–S108
25. Garber AJ, Abrahamson MJ, Barkzilay II, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2016: executive summary. Endocr Pract 2016;22:84–113

Acknowledgments
Medical writing support for this article was provided by Cherie Koch, PhD, of MedErgy and funded by Janssen Scientific Affairs, LLC. The authors retained full editorial control over the contents.
FEATURE ARTICLE

26. Cobble M. Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus. Diabetol Metab Syndr 2012;4:8

27. Lavalle-González FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomized trial. Diabetologia 2013;56:2582–2592

28. Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week, randomized trial. Diabetes Care 2013;36:2508–2515

29. Rodbard HW, Seufert J, Aggarwal N, et al. Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin. Diabetes Obes Metab 2016;18:812–819

30. Jabbour SA, Hardy E, Sugg J, Parikh S. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin in a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care 2014;37:740–750

31. Matthaei S, Catrinoiu D, Celinski A, et al. Randomized, double-blind trial of triple therapy with saxagliptin add-on to dapagliflozin plus metformin in patients with type 2 diabetes. Diabetes Care 2015;38:2018–2024

32. Mathieu C, Ranetti AE, Li D, et al. Randomized, double-blind, phase 3 trial of triple therapy with dapagliflozin add-on to saxagliptin plus metformin in type 2 diabetes. Diabetes Care 2015;38:2009–2017

33. DeFronzo RA, Lewin A, Patel S, et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care 2015;38:384–393

34. Lewin A, DeFronzo RA, Patel S, et al. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes Care 2015;38:394–402

35. Thayer S, Chow W, Korrer S, Aguilar R. Real-world evaluation of glycemic control among patients with type 2 diabetes mellitus treated with canagliflozin versus dipeptidyl peptidase-4 inhibitors. Curr Med Res Opin 2016;32:1087–1096

36. Diels J, Neslusan C. Comparative persistency with newer agents used to treat type 2 diabetes (T2DM) in the United States canagliflozin versus dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) agonists. Poster presented at the 20th Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Philadelphia, PA., 16–19 May 2015

37. Inzucchi SE, Zinman B, Wanner C, et al. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diaab Vasc Dis Res 2015;12:90–100

38. Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013;382:941–950

39. Blonde L, Stenløf K, Fung A, Xie J, Canovatchel W, Meiningler G. Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgrad Med 2016;128:371–380

40. Weir M, Januszewicz A, Gilbert R, et al. Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus. J Clin Hypertens (Greenwich) 2014;16:875–882

41. Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab 2014;16:1016–1027

42. Davies MJ, Trujillo A, Vijapurkar U, Damara Raj CV, Meiningler G. Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2015;17:426–429

43. Usiskin K, Kline L, Fung A, Mayer C, Meiningler G. Safety and tolerability of canagliflozin in patients with type 2 diabetes: pooled analysis of phase 2 diabetes. Postgrad Med 2014;126:16–34

44. Weidmann P, de Courten M, Ferrari P. Effect of diuretics on the plasma lipid profile. Eur Heart J 1992;13(Suppl. G):61–67

45. Neal B, Perkovic V, de Zeeuw D, et al. Rationale, design, and baseline characteristics of the CANagliflozin cardioVascular Assessment Study (CANVAS): a randomized placebo-controlled trial. Am Heart J 2013;166:217–223

46. Neal B, Perkovic V, Matthews DR, et al. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): a randomized, placebo-controlled trial. Diabetes Obes Metab 2017;19:387–393

47. Neal B, Perkovic V, Mahaffey KW, et al. Optimising the analysis strategy for the CANVAS Program: a pre-specified plan for the integrated analyses of the CANVAS and CANVAS-R trials. Diabetes Obes Metab 2017. Epub ahead of print (DOI:10.1111/ dom.12924)

48. U.S. Food and Drug Administration. FDA revises label of diabetes drug canagliflozin (Invokana, Invokamet) to include updates on bone fracture risk and new information on decreased bone mineral density [Internet]. Available from http://www.fda.gov/Drugs/DrugSafety/ucm461449.htm. Accessed 22 July 2016

49. Yale JF, Bakris G, Cariou B, et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2016;101:157–166

50. Integrated Assessment Study-Renal (CANVAS): a randomized, double-blind, phase 3 non-inferiority trial. Am Heart J 2016;128:371–380

51. Yale JF, Bakris G, Cariou B, et al. Effects of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus. J Clin Hypertens (Greenwich) 2014;16:875–882

52. Yale JF, Bakris G, Cariou B, et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2016;101:157–166

53. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117–2128

54. Watts NB, Bilezikian JP, Usiskin K, et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2016;101:157–166

55. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117–2128

56. Watts NB, Bilezikian JP, Usiskin K, et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2016;101:157–166

57. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117–2128

58. U.S. Food and Drug Administration. FDA briefing document: Endocrine and Metabolic Drug Advisory Committee meeting, June 28, 2016 [Internet]. Available from http://www.fda.gov/Drugs/DrugSafety/ucm500965.htm. Accessed 22 July 2016

59. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117–2128

60. Masro SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:313–322

61. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317–1326

62. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in
patients with type 2 diabetes. N Engl J Med 2013;369:1327–1335
63. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:232–242
64. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016;375:323–334
65. Thomas MC. Renal effects of empagliflozin in patients with type 2 diabetes. Ther Adv Endocrinol Metab 2014;5:53–61
66. Gilbert RE. Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering? Kidney Int 2014;86:693–700
67. Chao EC, Henry RR. SGLT2 inhibition: a novel strategy for diabetes treatment. Nat Rev Drug Discov 2010;9:551–559
68. Schwartz SS, Katz A. Sodium-glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin-metformin. Diabetes Metab Syndr Obes 2016;9:71–82